PatientsVille.com Logo

DRUG HYPERSENSITIVITY and Trazodone

PatientsVille

DRUG HYPERSENSITIVITY Symptoms and Causes

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions.

One problem is interactions, which may occur between

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as ginkgo and blood thinners
  • Drugs and diseases, such as aspirin and peptic ulcers

Interactions can change the actions of one or both drugs. The drugs might not work, or you could get side effects.

Side effects are unwanted effects caused by the drugs. Most are mild, such as a stomach aches or drowsiness, and go away after you stop taking the drug. Others can be more serious.

Drug allergies are another type of reaction. They can be mild or life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is more rare.

When you start a new prescription or over-the-counter medication, make sure you understand how to take it correctly. Know which other medications and foods you need to avoid. Ask your health care provider or pharmacist if you have questions.

Check out the latest treatments for DRUG HYPERSENSITIVITY

DRUG HYPERSENSITIVITY treatment research studies

Trazodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Trazodone Side Effects

Completed Suicide (190)
Priapism (134)
Insomnia (129)
Dizziness (118)
Nausea (113)
Depression (109)
Respiratory Arrest (108)
Headache (101)
Pain (100)
Vomiting (94)
Cardiac Arrest (94)
Fatigue (91)
Anxiety (89)
Dyspnoea (89)
Confusional State (88)
Serotonin Syndrome (86)
Overdose (86)
Diarrhoea (80)
Suicide Attempt (79)
Asthenia (68)
Suicidal Ideation (34)
Fall (33)
Somnolence (30)
Feeling Abnormal (30)
Convulsion (29)
Arthralgia (28)
Toxicity To Various Agents (28)
Malaise (28)
Pain In Extremity (28)
Rash (28)
Weight Increased (27)
Hypotension (27)
Gait Disturbance (26)
Product Quality Issue (26)
Intentional Overdose (26)
Myalgia (26)
Constipation (25)
Tremor (24)
Loss Of Consciousness (23)
Condition Aggravated (23)
Muscle Spasms (22)
Back Pain (22)
Cardio-respiratory Arrest (22)
Electrocardiogram Qt Prolonged (21)
Pyrexia (21)
Palpitations (21)
Hallucination (20)
Amnesia (20)
Erectile Dysfunction (19)
Paraesthesia (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

DRUG HYPERSENSITIVITY Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Conditions: Delirium;   Agitation
Interventions: Drug: Risperidone;   Drug: Trazodone;   Drug: Placebo
Outcome Measures: The number of days patients are without delirium during the study period (delirium-free days);   Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU);   Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours;   The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day;   The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent;   The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication;   The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered;   The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered;   The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.;   The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days);   The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline);   The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   All-cause mortality and 28-day mortality
2 Unknown  A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Condition: Depression
Interventions: Drug: Trazodone;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale-17 score;   Changes in HAMA-14 score;   CGI-Severity of illness and CGI-Global improvement;   Changes in evaluation of sleep quality and sexual dysfunction;   Rate changes of responders/patients
3 Recruiting Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia
Condition: Insomnia
Interventions: Drug: Trazodone;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Change from Baseline in objective sleep duration at 9 months;   Change from Baseline in Subjective Severity of Sleep Disturbance & Subjective Sleep Duration at 9 months
4 Recruiting The Effects of Trazodone on Sleep Apnea Severity
Condition: Sleep Apnea, Obstructive
Interventions: Drug: Placebo pill;   Drug: Trazodone
Outcome Measures: Apnea-Hypopnea Index;   Arousal threshold
5 Unknown  Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations
Condition: Healthy
Interventions: Drug: Trazodone;   Drug: Quetiapine;   Drug: Pindolol;   Procedure: Blood Collection
Outcome Measure: Plasma levels of Medication
6 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
7 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
8 Recruiting Sequenced Therapies for Comorbid and Primary Insomnias
Conditions: Insomnia Comorbid to Psychiatric Disorder;   Primary Insomnia
Interventions: Behavioral: Behavioral Insomnia Therapy;   Drug: Zolpidem;   Drug: Trazodone;   Behavioral: Cognitive Therapy
Outcome Measure: Insomnia Severity Index- Change from Baseline (Remission)
9 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: Trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
10 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
11 Recruiting The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
Condition: Chest Pain
Interventions: Drug: Marinol;   Drug: Placebo
Outcome Measures: Frequency of chest pain episodes;   Frequency of chest pain in treatment group vs baseline;   Intensity of chest pain episodes;   Sensory thresholds for first sensation;   Frequency of reactive esophageal contractions;   Amplitude of reactive esophageal contractions;   Area under the curve of reactive esophageal contractions;   Duration of chest pain episodes;   Sensory thresholds for discomfort;   Sensory thresholds for pain